Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
INCY 
Incyte Corporation (INCY)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/01/2025: INCY (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Analysis of Past Performance
Type Stock | Historic Profit -10.28% | Avg. Invested days 35 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 04/01/2025 |
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 11.79B USD | Price to earnings Ratio 406.07 | 1Y Target Price 74.53 |
Price to earnings Ratio 406.07 | 1Y Target Price 74.53 | ||
Volume (30-day avg) 1975151 | Beta 0.76 | 52 Weeks Range 50.35 - 83.95 | Updated Date 04/1/2025 |
52 Weeks Range 50.35 - 83.95 | Updated Date 04/1/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 0.15 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 0.77% | Operating Margin (TTM) 25.34% |
Management Effectiveness
Return on Assets (TTM) 0.86% | Return on Equity (TTM) 0.75% |
Valuation
Trailing PE 406.07 | Forward PE 10.07 | Enterprise Value 9673020158 | Price to Sales(TTM) 2.78 |
Enterprise Value 9673020158 | Price to Sales(TTM) 2.78 | ||
Enterprise Value to Revenue 2.28 | Enterprise Value to EBITDA 23.7 | Shares Outstanding 193524000 | Shares Floating 161331574 |
Shares Outstanding 193524000 | Shares Floating 161331574 | ||
Percent Insiders 1.99 | Percent Institutions 96.76 |
Analyst Ratings
Rating 3.78 | Target Price 79.42 | Buy 2 | Strong Buy 10 |
Buy 2 | Strong Buy 10 | ||
Hold 14 | Sell 1 | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Incyte Corporation
Company Overview
History and Background
Incyte Corporation was founded in 2002. Initially focused on genomics research, it transitioned to drug discovery and development, achieving significant milestones with the approval of Jakafi and other targeted therapies.
Core Business Areas
- Hematology/Oncology: Focuses on developing and commercializing therapies for hematologic malignancies and solid tumors. Key product is Jakafi (ruxolitinib).
- Dermatology: Focuses on developing and commercializing therapies for dermatological conditions. Key product is Opzelura (ruxolitinib) cream.
- Research and Development: Conducts research to discover and develop new therapeutic candidates across various disease areas.
Leadership and Structure
Herve Hoppenot serves as the CEO. The company has a typical corporate structure with functional departments like R&D, Commercial, and Finance.
Top Products and Market Share
Key Offerings
- Jakafi (ruxolitinib): A JAK1/JAK2 inhibitor approved for myelofibrosis, polycythemia vera, and acute graft-versus-host disease. Revenue in 2023 was approximately $2.68 billion globally (net product revenue + royalties). Competitors include Bristol Myers Squibb (Reblozyl), Sierra Oncology (Momelotinib).
- Opzelura (ruxolitinib) cream: A topical formulation of ruxolitinib approved for atopic dermatitis and vitiligo. Revenue in 2023 was approximately $455 million globally. Competitors include Regeneron (Dupixent) for atopic dermatitis.
- Pemazyre (pemigatinib): A FGFR2 inhibitor approved for cholangiocarcinoma. Revenue in 2023 was approximately $98 million globally. Competitors include QED Therapeutics(Truseltiq).
Market Dynamics
Industry Overview
The pharmaceutical industry is highly competitive and regulated, with increasing pressure to develop innovative therapies and control costs. The oncology and dermatology segments are experiencing significant growth due to aging populations and increasing prevalence of chronic diseases.
Positioning
Incyte is a mid-sized biopharmaceutical company with a strong focus on targeted therapies. Its competitive advantages include its expertise in kinase inhibitors and its established commercial infrastructure. Its success also depends on their partnerships with other big Pharmaceutical companies like Novartis and Eli Lilly
Total Addressable Market (TAM)
The global oncology and dermatology markets are estimated to be worth hundreds of billions of dollars. Incyte is positioned to capture a significant share of these markets with its existing products and pipeline candidates.
Upturn SWOT Analysis
Strengths
- Successful commercialization of Jakafi
- Strong pipeline of drug candidates
- Expertise in kinase inhibitors
- Partnerships with major pharmaceutical companies
- Growing revenues in dermatology with Opzelura
Weaknesses
- Reliance on Jakafi for a significant portion of revenue
- Exposure to generic competition as patents expire
- Dependence on partners for successful launch of some products
- Potential for clinical trial failures
- Regulatory hurdles for new drug approvals
Opportunities
- Expanding indications for existing products
- Developing novel therapies for unmet medical needs
- Acquiring or licensing new technologies
- Expanding into new geographic markets
- Advancements in personalized medicine to increase the efficacy of Incyte products
Threats
- Competition from other pharmaceutical companies
- Pricing pressures from payers and governments
- Changes in regulatory requirements
- Clinical trial failures of key pipeline candidates
- Generic erosion of Jakafi sales
Competitors and Market Share
Key Competitors
- BMY
- REGN
- VRTX
- MRK
Competitive Landscape
Incyte competes with larger pharmaceutical companies and smaller biotechnology firms. Its strengths include its expertise in kinase inhibitors and its established commercial infrastructure. However, it faces increasing competition from new therapies and generic erosion.
Major Acquisitions
Villaris Therapeutics
- Year: 2022
- Acquisition Price (USD millions): 143
- Strategic Rationale: Acquisition of Villaris added anti-IL-15 antibody program to Incyte's portfolio, further strengthening the company's presence in immuno-dermatology.
Growth Trajectory and Initiatives
Historical Growth: Incyte has experienced significant revenue growth over the past decade, driven by the success of Jakafi.
Future Projections: Analysts project continued revenue growth for Incyte, driven by Opzelura and pipeline candidates. Growth rate is expected to moderate as Jakafi sales plateau.
Recent Initiatives: Recent initiatives include expanding the indications for Opzelura, advancing pipeline candidates through clinical trials, and forming strategic partnerships.
Summary
Incyte is a biopharmaceutical company that has achieved commercial success with Jakafi and is positioned for growth with Opzelura. While its reliance on Jakafi presents a risk, the company's pipeline and strategic initiatives offer opportunities for diversification. Threats include competition, pricing pressures, and regulatory hurdles. Incyte should remain focused on expanding into new indications, continuing partnerships, and minimizing expenses.
Similar Companies
BMY
Bristol-Myers Squibb Company
BMY
Bristol-Myers Squibb Company
LLY
Eli Lilly and Company
LLY
Eli Lilly and Company
MRK
Merck & Company Inc
MRK
Merck & Company Inc
NVS
Novartis AG ADR
NVS
Novartis AG ADR
REGN
Regeneron Pharmaceuticals Inc
REGN
Regeneron Pharmaceuticals Inc
VRTX
Vertex Pharmaceuticals Inc
VRTX
Vertex Pharmaceuticals Inc
Sources and Disclaimers
Data Sources:
- Incyte Corporation Annual Reports
- SEC Filings
- Analyst Reports
- Company Press Releases
Disclaimers:
The data provided is for informational purposes only and should not be considered investment advice. Market share estimates are approximate and may vary depending on the source.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Incyte Corporation
Exchange NASDAQ | Headquaters Wilmington, DE, United States | ||
IPO Launch date 1993-11-04 | Chairman, President & CEO Mr. Herve Hoppenot | ||
Sector Healthcare | Industry Biotechnology | Full time employees 2617 | Website https://www.incyte.com |
Full time employees 2617 | Website https://www.incyte.com | ||
Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics in the United States, Europe, Canada, and Japan. The company offers JAKAFI (ruxolitinib) for the treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for treating relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a selective fibroblast growth factor receptor kinase inhibitor for the treatment of unresectable biliary tract cancer, metastatic cholangiocarcinoma, and myeloid/lymphoid neoplasms; ICLUSIG (ponatinib), a kinase inhibitor to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma; and NIKTIMVO (axatilimab-csfr) for treating chronic graft-versus-host disease, as well as OPZELURA (ruxolitinib) cream for treating atopic dermatitis. Its clinical stage products include INCB123667 (CDK2) for ovarian cancer; INCB161734 (KRASG12D) for cancers; INCA33890 (TGFßR2xPD-1) for solid tumors; Ruxolitinib cream for mild to moderate hidradenitis suppurativa (HS); Povorcitinib for HS, nonsegmental vitiligo, prurigo nodularis, and asthma and chronic spontaneous urticaria; INCB000262 (MRGPRX2) and INCB000547 (MRGPRX4) for systemic immune and neuro-immune disorders; INCA034460 (anti-CD122) for vitiligo; and Zilurgisertib (ALK2) for fibrodysplasia ossificans progressive. It has collaboration with Genesis Therapeutics, Inc. The company sells its products to specialty and retail pharmacies, hospital pharmacies, and specialty distributors and wholesalers. The company was formerly known as Incyte Genomics Inc and changed its name to Incyte Corporation in March 2003. Incyte Corporation was incorporated in 1991 and is headquartered in Wilmington, Delaware.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.